Drug news
FDA approves FluBlok Vaccine for Influenza-Protein Sciences
The FDA has approved Flublok vaccine, from Protein Sciences, for Influenza, in all adults aged 18 years and older, granting approval for use in people 50 and older under the accelerated approval of biological products regulations. Flublok, the first recombinant protein-based vaccine for the prevention of seasonal Influenza disease, was approved by FDA in January 2013. Earlier this year the FDA approved a shelf life extension for Flublok to 6 months.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins